Cargando…

Burosumab for the Treatment of Tumor‐Induced Osteomalacia

Tumor‐induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T‐CL201 is an ongoing, open‐label, phase 2 study investigating the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jan de Beur, Suzanne M, Miller, Paul D, Weber, Thomas J, Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, San Martin, Javier, Carpenter, Thomas O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247961/ https://www.ncbi.nlm.nih.gov/pubmed/33338281 http://dx.doi.org/10.1002/jbmr.4233

Ejemplares similares

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
por: Imanishi, Yasuo, et al.
Publicado: (2020)

Long-term use of burosumab for the treatment of tumor-induced osteomalacia
por: Crotti, C., et al.
Publicado: (2022)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report
por: Oe, Yuki, et al.
Publicado: (2021)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
por: Hartley, Iris R., et al.
Publicado: (2022)

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases
por: Bosman, Ariadne, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

PSAT218 Technetium 99m-Methyl Diphosphonate (99mTc MDP) Radioguided Surgery in Patient With Tumor-Induced Osteomalacia (TIO)
por: Khan, Sara A, et al.
Publicado: (2022)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report
por: Miyaoka, Daichi, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia
por: Jan de Beur, Suzanne M., et al.
Publicado: (2022)

Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience
por: Dahir, Kathryn, et al.
Publicado: (2021)

Osteomalacia
por: Fothergill, W. E.
Publicado: (1901)

Osteomalacia
Publicado: (1914)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
por: Ertl, Diana-Alexandra, et al.
Publicado: (2022)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

Osteomalacia in the Elderly
por: Sharland, D.E.
Publicado: (1982)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
por: Jurca, Claudia Maria, et al.
Publicado: (2022)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Osteomalacia following gastrectomy.
por: Piggot, J.
Publicado: (1965)

Cannot write session to /tmp/vufind_sessions/sess_u8el1ak5344m9nrcg1vakbnv37